ecrin-mdr-crcClinical2018IPD Sharing (as of April 2023): UndecidedMalignant neoplasm of colon, Malignant neoplasm of rectumMetastatic Colorectal CancerColorectal NeoplasmsC18.9, C20RAS wild-type Metastatic Colorectal CancerMetastatic Colorectal CancerMalignant Neoplasm Of Colon, Malignant Neoplasm Of RectumColorectal NeoplasmsC18.9, C20Ras Wild-type Metastatic Colorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2262710Iran1IrinotecanLeucovorinRAS Wild-typeCetuximabFluorouracilECRIN MDRRecruitingfalseComparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux (Merck) in Metastatic Colorectal CancerThe study is designed as phase III, randomized, two armed, parallel, double blind (patient and assessor blinded), active controlled, and equivalency clinical trial with primary endpoint of Progression-Free Survival of Cetuximab (produced by CinnaGen) compared with Erbitux (Cetuximab, the reference drug) in patients with RAS wild-type Metastatic Colorectal Cancer with the allocation ratio of 2:1.Patients who met the following criteria could be recruited to receive the mentioned intervention randomly. Inclusion criteria: Male or female older than 18 years old, histologically confirmed adenocarcinoma of the colon or rectum which is metastatic, having one or more bi-dimensionally measurable lesions as defined by RECIST criteria, tumor that could not be resected for curative purposes,ECOG performance status score of 2 or less,life expectancy of longer than 3 months (clinical assessment),evidence of tumor EGFR expression (expanded wild-type RAS),adequate organ and marrow function as defined: ANC ≥ 1,500/mm3 Plt ≥ 100,000/mm3 Hb ≥ 9 g/dL (may have had blood transfusions) AST/ALT ≤ 2.5 IULN or ≤ 5 IULN with known liver metastases Total bilirubin ≤ 1.5 IULN Serum Creatinine ≤ 1.5 IULN INR ≤ 1.5 and PTT ≤ 1.5 IULN2018-01-152262710NCT03391934IRCT2017110821315N10